Elevated Cortisol Symptoms: Drugs That Cause or Treat It

How Cortisol Works and Why Drug Effects Matter

Cortisol is a glucocorticoid hormone produced by the adrenal cortex under control of the hypothalamic-pituitary-adrenal (HPA) axis. The hypothalamus releases corticotropin-releasing hormone, which signals the pituitary to secrete adrenocorticotropic hormone (ACTH), and ACTH drives the adrenal glands to synthesize cortisol 1. Normal diurnal secretion peaks in the early morning and falls through the evening. Any drug that either adds exogenous glucocorticoid activity or disrupts the HPA feedback loop can push cortisol signaling into a pathologic range.

The clinical picture of excess cortisol, whether from a pituitary adenoma, an adrenal tumor, or a prescription bottle, follows the same pattern: central adiposity, proximal muscle wasting, purple striae wider than 1 cm, new-onset hyperglycemia, hypertension, and neuropsychiatric changes including insomnia, anxiety, and cognitive slowing 2. The 2015 Endocrine Society clinical practice guideline states that "Cushing's syndrome should be suspected in patients with multiple and progressive features, particularly those that are more predictive of the syndrome" 2. Distinguishing drug-induced from endogenous causes is the first branch point in any workup.

Drugs That Raise Cortisol Levels

Exogenous glucocorticoids cause the vast majority of Cushingoid presentations worldwide. Prednisone, prednisolone, dexamethasone, methylprednisolone, and hydrocortisone all deliver supraphysiologic glucocorticoid activity when used at doses above physiologic replacement (roughly 5 mg of prednisone or equivalent) for more than a few weeks 3. A 2018 population-based study in Denmark found that approximately 3% of the adult population used systemic glucocorticoids in a given year, and the rate of iatrogenic Cushing syndrome among chronic users was estimated between 1.3% and 5.7% depending on dose and duration 3.

Inhaled corticosteroids can also produce systemic effects at high doses. Fluticasone propionate at 1 to 000 mcg/day or higher has been linked to adrenal suppression and, in some patients, overt Cushingoid features, particularly in children 4. Topical and intra-articular corticosteroids occasionally cause systemic cortisol excess, especially with occlusive application or frequent joint injections 5.

Beyond steroids, a smaller group of medications influences cortisol through indirect mechanisms. Short list:

• Megestrol acetate, a progestational agent used for cancer-related cachexia, has intrinsic glucocorticoid activity and can produce Cushingoid changes and adrenal suppression 6.
• Ritonavir and cobicistat, both CYP3A4 inhibitors used in HIV therapy, dramatically slow the metabolism of co-administered inhaled or injected corticosteroids, leading to accumulated steroid exposure and iatrogenic Cushing syndrome even from "local" steroid formulations 7.
• Certain antipsychotics and antidepressants can transiently activate the HPA axis. Chronic HPA hyperactivation is documented in major depressive disorder itself, though drug-specific contributions are harder to isolate 8.

The critical distinction is that exogenous glucocorticoid use suppresses endogenous ACTH and cortisol. Measured serum cortisol may actually be low while synthetic steroid activity remains high. A thorough medication history, including over-the-counter creams and supplements, is the single most important step before ordering any biochemical test.

How Drug-Induced Cortisol Elevation Is Diagnosed

The Endocrine Society guideline recommends screening with at least two of three first-line tests: 24-hour urinary free cortisol (UFC), late-night salivary cortisol, or the 1 mg overnight dexamethasone suppression test (DST) 2. For drug-induced cases, interpretation requires nuance. Exogenous steroids will suppress endogenous cortisol, so a low morning cortisol paired with Cushingoid features points directly at the prescription as the source.

If exogenous steroids have been excluded and screening tests are positive, ACTH measurement separates ACTH-dependent from ACTH-independent causes. ACTH levels above 20 pg/mL suggest a pituitary or ectopic source. Levels below 5 pg/mL point toward an adrenal tumor 9. Dr. Lynnette Nieman of the National Institute of Diabetes and Digestive and Kidney Diseases has noted that "the accuracy of first-line screening tests is high but not perfect, and clinicians should repeat borderline results before pursuing advanced imaging" 9.

A practical clinical sequence:

1. Review every medication, including inhalers, topicals, joint injections, and supplements.
2. Measure morning serum cortisol and ACTH while the patient is off any exogenous steroid for at least 24 hours (if safe to hold).
3. Order two first-line screening tests if exogenous steroids are excluded and clinical suspicion persists.
4. Refer to endocrinology if biochemical testing confirms autonomous cortisol excess.

FDA-Approved Drugs That Treat Hypercortisolism

When surgery is not feasible, has failed, or serves as a bridge to definitive treatment, pharmacotherapy targets cortisol at three levels: steroidogenesis inhibitors block cortisol synthesis in the adrenal gland, a glucocorticoid receptor antagonist blocks cortisol action at the tissue level, and pituitary-directed agents reduce ACTH secretion from a corticotroph adenoma.

Steroidogenesis Inhibitors

Osilodrostat (Isturisa) inhibits 11-beta-hydroxylase, the final enzyme in cortisol biosynthesis. The LINC-3 trial (N=137) demonstrated that 77% of patients with Cushing disease achieved normal UFC at week 48, with a mean UFC reduction exceeding 90% from baseline 10. Common adverse effects include adrenal insufficiency (requiring dose titration), QTc prolongation, nausea, and hirsutism from accumulated androgen precursors. The FDA approved osilodrostat in March 2020 for adults with Cushing disease who cannot undergo pituitary surgery or have not been cured by it.

Ketoconazole inhibits several cytochrome P450 enzymes involved in steroidogenesis, including CYP11B1, CYP17A1, and CYP11A1. Off-label use for Cushing syndrome dates back decades, and a large retrospective French study (N=200) showed UFC normalization in about 49% of patients 11. Hepatotoxicity is the primary concern. The European Medicines Agency approved ketoconazole specifically for Cushing syndrome (brand name Ketoconazole HRA) in 2014, while in the U.S., its use for hypercortisolism remains off-label 11. Liver function tests must be monitored every one to two weeks during the first three months.

Metyrapone (Metopirone) also inhibits 11-beta-hydroxylase. It has a rapid onset, making it useful in severe or acute hypercortisolism. A 2015 retrospective analysis of 195 patients reported UFC normalization in 43% to 76% depending on the underlying etiology 12. In the U.S., metyrapone is used off-label for cortisol lowering; it carries formal approval in several European countries. Side effects include hypokalemia from mineralocorticoid precursor accumulation, hirsutism, and gastrointestinal upset.

Levoketoconazole (Recorlev) is the 2S,4R enantiomer of ketoconazole, approved by the FDA in December 2021 for endogenous hypercortisolism. The SONICS trial (N=94) demonstrated that 31% of patients achieved normalization of UFC at the end of the maintenance phase 13. Its advantage over racemic ketoconazole is a potentially improved hepatic safety profile, though liver monitoring is still required.

Glucocorticoid Receptor Antagonist

Mifepristone (Korlym) blocks the glucocorticoid receptor (GR) and, at higher doses, the progesterone receptor. The FDA approved it in 2012 specifically for hyperglycemia secondary to endogenous hypercortisolism in patients who are not surgical candidates. Because it acts at the receptor rather than reducing cortisol production, serum cortisol and ACTH levels actually rise during treatment, and clinicians must rely on clinical endpoints (glucose control, blood pressure, weight) rather than biochemical markers to gauge efficacy 14. The SEISMIC study (N=50) showed that 60% of patients with diabetes or glucose intolerance met the primary glucose endpoint 14. Because mifepristone is also an antiprogestin, it is contraindicated in pregnancy and in women using a progesterone-containing IUD.

Pituitary-Directed Agent

Pasireotide (Signifor) is a somatostatin receptor ligand with high affinity for the sst5 receptor subtype, which is overexpressed on corticotroph adenomas. The phase III trial (N=162) demonstrated UFC normalization in 26% of patients at month 6 with the 900 mcg twice-daily dose 15. Hyperglycemia is the most clinically significant adverse effect, occurring in up to 73% of patients in the trial, often requiring initiation or intensification of diabetes therapy. A long-acting intramuscular formulation (Signifor LAR) is available for monthly dosing.

Managing Exogenous Steroid-Induced Cortisol Excess

The treatment for iatrogenic Cushing syndrome is conceptually simple: taper and discontinue the offending glucocorticoid. The execution is not simple. Abrupt withdrawal after prolonged use risks adrenal crisis because the HPA axis may remain suppressed for months. The Endocrine Society recommends reducing the glucocorticoid dose gradually, often by 10% to 20% every one to two weeks, while monitoring for symptoms of adrenal insufficiency such as fatigue, hypotension, nausea, and arthralgias 16.

Morning serum cortisol measured after holding the steroid dose for 24 hours can guide the taper. A value above 10 mcg/dL suggests recovering adrenal function. Values below 5 mcg/dL indicate ongoing suppression and the need for continued physiologic replacement 16. A cosyntropin stimulation test (250 mcg IV ACTH with cortisol measured at 30 and 60 minutes) provides a more definitive assessment. A stimulated cortisol above 18 mcg/dL is generally considered adequate.

For patients who require ongoing immunosuppression or anti-inflammatory therapy, steroid-sparing agents (methotrexate, azathioprine, biologic therapies) should be prioritized wherever the underlying disease permits. Switching from systemic to topical or inhaled formulations also reduces cumulative exposure.

When to Worry About Elevated Cortisol Symptoms

Not every patient with one or two cortisol-related complaints has clinically significant hypercortisolism. Obesity, depression, poorly controlled type 2 diabetes, and polycystic ovary syndrome can all produce mild cortisol elevations and overlapping symptoms, a state sometimes called "pseudo-Cushing" or "physiologic hypercortisolism" 17. The 2008 Endocrine Society guideline recommends reserving biochemical testing for patients with "unusual features for age" (osteoporosis in a 30-year-old, hypertension with hypokalemia in a young adult) or those with multiple progressive features.

Red flags that warrant prompt evaluation:

• Unexplained proximal muscle weakness (difficulty rising from a chair or climbing stairs)
• Wide (>1 cm) purple or violaceous striae
• Facial plethora and dorsocervical fat pad ("buffalo hump") developing over months
• New fragility fractures or rapid bone density loss
• Hypokalemia paired with hypertension, especially in a younger patient

A single elevated late-night salivary cortisol does not confirm Cushing syndrome. The guideline requires at least two abnormal screening tests before proceeding to confirmatory evaluation 2.

Emerging Therapies and Pipeline Agents

Several investigational drugs may expand treatment options. Relacorilant, a selective glucocorticoid receptor antagonist without antiprogestin activity, completed the phase III GRACE trial (N=152). Results showed significant improvement in glucose tolerance compared to placebo, with a safety profile that avoids the progesterone-receptor-mediated effects of mifepristone 18. The FDA accepted the new drug application for priority review.

Osilodrostat is also being studied in adrenal and ectopic Cushing syndrome beyond its current Cushing disease indication. And combination strategies pairing a steroidogenesis inhibitor with a pituitary-directed agent are in early investigation, aiming to improve normalization rates while keeping individual drug doses (and side effects) lower.

For patients on chronic glucocorticoids, research into selective glucocorticoid receptor modulators (SEGRMs) aims to retain anti-inflammatory benefit while reducing metabolic side effects, though no SEGRM has reached late-stage trials for this indication as of mid-2026 19.